NDC 50242-053

Rituxan

Rituximab

Rituxan is a Intravenous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Rituximab.

• Product ID: 50242-053_02e8a40e-4443-4bd5-acff-ad7f3244d43c
• NDC: 50242-053
• Product Type: Human Prescription Drug
• Proprietary Name: Rituxan
• Generic Name: Rituximab
• Dosage Form: Injection, Solution
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 1997-11-26
• Marketing Category: BLA / BLA
• Application Number: BLA103705
• Labeler Name: Genentech, Inc.
• Substance Name: RITUXIMAB
• Active Ingredient Strength: 10 mg/mL
• Pharm Classes: CD20-directed Antibody Interactions [MoA],CD20-directed Cytolytic Antibody [EPC]
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 50242-053-06

1 VIAL, SINGLE-USE in 1 CARTON (50242-053-06) > 50 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 1997-11-26
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 50242-053-06 [50242005306]

Rituxan INJECTION, SOLUTION

• Marketing Category: BLA
• Application Number: BLA103705
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 1997-11-26

Drug Details

Active Ingredients

Ingredient	Strength
RITUXIMAB	10 mg/mL

OpenFDA Data

• SPL SET ID: b172773b-3905-4a1c-ad95-bab4b6126563
• Manufacturer:
  • Genentech, Inc.
• UNII:
  • 4F4X42SYQ6
• RxNorm Concept Unique ID - RxCUI:
  • 1657862
  • 1657868
  • 1657867
  • 1657864

Pharmacological Class

• CD20-directed Antibody Interactions [MoA]
• CD20-directed Cytolytic Antibody [EPC]

NDC Crossover Matching brand name "Rituxan" or generic name "Rituximab"

NDC	Brand Name	Generic Name
50242-051	Rituxan	rituximab
50242-053	Rituxan	rituximab